

RESEARCH ARTICLE

Annexin A8 Identifies a Subpopulation of Transiently Quiescent c-Kit Positive Luminal Progenitor Cells of the Ductal Mammary Epithelium

Juan Manuel Iglesias^{1,2}, Claire J. Cairney¹, Roderick K. Ferrier¹, Laura McDonald³, Kelly Soady⁴, Howard Kendrick⁵, Marie-Anne Pringle^{1,6}, Reginald O. Morgan⁷, Finian Martin⁸, Matthew J. Smalley⁵, Karen Blyth³, Torsten Stein^{1*}

1 Institute of Cancer Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom, **2** Synpromics Limited, Edinburgh, United Kingdom, **3** CRUK Beatson Institute, Glasgow, United Kingdom, **4** Medical Research Council Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom, **5** European Cancer Stem Cell Research Institute, Cardiff School of Biosciences, Cardiff University, Cardiff, United Kingdom, **6** Institute of Molecular Cell and Systems Biology, University of Glasgow, Glasgow, United Kingdom, **7** Department of Biochemistry and Molecular Biology and the Institute of Biotechnology of Asturias (IUBA), University of Oviedo, Oviedo, Spain, **8** Conway Institute and School of Biomolecular and Biomedical Science, University College Dublin, Belfield, Dublin, Ireland

* Torsten.Stein@glasgow.ac.uk



OPEN ACCESS

Citation: Iglesias JM, Cairney CJ, Ferrier RK, McDonald L, Soady K, Kendrick H, et al. (2015) Annexin A8 Identifies a Subpopulation of Transiently Quiescent c-Kit Positive Luminal Progenitor Cells of the Ductal Mammary Epithelium. PLoS ONE 10(3): e0119718. doi:10.1371/journal.pone.0119718

Academic Editor: Tiffany Seagroves, University of Tennessee Health Science Center, UNITED STATES

Received: June 12, 2012

Accepted: February 2, 2015

Published: March 24, 2015

Copyright: © 2015 Iglesias et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: The work was funded by a Breakthrough Breast Cancer grant (BGU05/06) and Breast Cancer Campaign grant (2012NovPR006) to TS. ROM was funded by grant BFU2007-67876 from the Ministerio de Ciencia e Innovación, Spain, and co-financed by FEDER. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Synpromics Ltd. provided support in the form of a salary for author JMI but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific

Abstract

We have previously shown that Annexin A8 (ANXA8) is strongly associated with the basal-like subgroup of breast cancers, including BRCA1-associated breast cancers, and poor prognosis; while in the mouse mammary gland *AnxA8* mRNA is expressed in low-proliferative isolated pubertal mouse mammary ductal epithelium and after enforced involution, but not in isolated highly proliferative terminal end buds (TEB) or during pregnancy. To better understand ANXA8's association with this breast cancer subgroup we established ANXA8's cellular distribution in the mammary gland and ANXA8's effect on cell proliferation. We show that ANXA8 expression in the mouse mammary gland was strong during pre-puberty before the expansion of the rudimentary ductal network and was limited to a distinct subpopulation of ductal luminal epithelial cells but was not detected in TEB or in alveoli during pregnancy. Similarly, during late involution its expression was found in the surviving ductal epithelium, but not in the apoptotic alveoli. Double-immunofluorescence (IF) showed that ANXA8 positive (+ve) cells were ER-alpha negative (-ve) and mostly quiescent, as defined by lack of Ki67 expression during puberty and mid-pregnancy, but not terminally differentiated with ~15% of ANXA8 +ve cells re-entering the cell cycle at the start of pregnancy (day 4.5). RT-PCR on RNA from FACS-sorted cells and double-IF showed that ANXA8+ve cells were a subpopulation of c-kit +ve luminal progenitor cells, which have recently been identified as the cells of origin of basal-like breast cancers. Over expression of ANXA8 in the mammary epithelial cell line Kim-2 led to a G₀/G₁ arrest and suppressed Ki67 expression, indicating cell cycle exit. Our data therefore identify ANXA8 as a potential mediator of

role of this author is articulated in the 'author contributions' section.

Competing Interests: The authors have the following interests. JMI is employed by Synpromics Ltd. There are no patents, products in development, or marketed products to declare. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.

quiescence in the normal mouse mammary ductal epithelium, while its expression in basal-like breast cancers may be linked to ANXA8's association with their specific cells of origin.

Introduction

Annexins form a superfamily of calcium-dependent lipid-binding proteins broadly distributed throughout all eukaryotic phyla and even some bacteria and archaea. These proteins feature unique homologous repeats that contain the calcium and lipid binding sites. However, their calcium-dependent lipid-binding ability is not a universal feature of annexins since some of them have partially or completely lost their type 2 calcium binding sites through evolutionary divergence [1]. This patterned structural diversity corresponds to a functional adaptation characteristic of individual subfamilies that ranges from membrane and cytoskeletal organisation to the regulation of membrane traffic and signalling. Annexins have also been shown to act as extracellular anti-inflammatory and anti-coagulant factors as cell surface proteins, and some have even been proposed to have nuclear roles [2–5]. They are further involved in phagocytosis as well as endo- and exocytosis (for reviews see [6–9]). Most initial studies have focused on their calcium-dependent membrane-binding properties but these may not be universal nor essential features for their action. Function-oriented studies have described annexins involved in cell growth and proliferation [10–12] and alterations of their expression have been associated with cancer subtypes and other diseases [13–16].

ANXA8 is one of the least characterised members of the annexin superfamily. ANXA8 was first described as an inhibitor of phospholipase A2 and as a blood coagulation factor (VAC- β) because of its structural similarity to VAC- α (ANXA5, lipocortin V) [17]. It was later found to be specifically over expressed in acute promyelocytic leukaemia (APL) where it was repressible by all-trans retinoic acid (ATRA) [18–21]. Deregulation of ANXA8 has since then been found in several other malignancies, including infiltrating adenocarcinomas of the pancreas [22], cholangiocarcinoma [23], malignant pleural mesothelioma [24], melanoma [25], squamous carcinoma of the uterine cervix [26], esophageal adenocarcinoma and Barrett's metaplasia [27]. Perou et al. (2000) identified *Anxa8* by microarray analysis as part of an RNA signature for a subgroup of breast cancers with poor prognosis they called basal-like breast cancers because of their expression of basal cell associated cytokeratins (CK) 5 and 17 [28]. Our own work has previously established that ANXA8 protein is not detected in the majority of breast cancers but in a distinct subset of CK5 positive, oestrogen receptor (ER) α and progesterone receptor (PgR) negative breast cancers with poor prognosis and in a high percentage of BRCA1-associated cancers [29], confirming the RNA profiles by Perou et al. [28] and Sorlie et al. [30].

ANXA8 has been linked to the formation of endosomes and epidermal growth factor receptor (EGFR) turnover in Hela cells [31], and is required for efficient cell surface presentation of CD63 and P-selectin to allow leukocyte recruitment by activated endothelial cells [32]. Other studies identified ANXA8 as a target for p53-activated DNA damage response after treatment with adriamycin/doxorubicin of mouse embryonic fibroblasts [33] or when p53 was over expressed in Saos2 cells [34]. However its biological function in the mammary gland is still unknown.

We have previously shown that *Anxa8* mRNA was up-regulated during mouse mammary gland involution [29], a multi-step process in which the alveolar epithelium regresses by programmed cell death to a near pre-pregnant morphology [27, 32]. In the pubertal gland, *Anxa8* mRNA was found in enzymatically isolated epithelial ducts but not in terminal end buds [29].

In general, *Anxa8* mRNA abundance was highest during periods of widespread cell death or low proliferation. To get a better understanding of ANXA8's role during mammary gland development we aimed to determine its cellular distribution at different developmental time points, to assess its association with different epithelial subpopulations, and to study the effect of ANXA8 expression *in vitro*.

Here we show for the first time that ANXA8 is expressed in a distinct quiescent subpopulation of ER α -ve cells of the ductal mammary epithelium during puberty and early pregnancy, but not in proliferating TEB or alveoli. During late involution, ANXA8 was only detected in the surviving epithelium, but not in the apoptotic cells. qRT-PCR using mRNA from FACS-sorted cells showed that *Anxa8* was strongly associated with c-kit+ve/ER α -ve luminal progenitor cells (CD45⁻, CD24^{+/high}, Sca1⁻, cd49f⁻, c-kit⁺), and triple-IF staining associated ANXA8 expression with a transiently quiescent subpopulation of the ductal luminal epithelium. Over expression in the mammary epithelial cell line KIM-2 altered the cell morphology and removed these cells from the cell cycle. Our data therefore strongly link ANXA8 to a subpopulation of c-kit+ve/ER α -ve ductal luminal epithelial progenitor cells and links ANXA8 function with cellular quiescence in the mammary epithelium. As this cell population was recently identified as the likely cells of origin for basal-like breast cancers, ANXA8's expression in this cancer subgroup may therefore be a consequence of their cells of origin and thus a useful diagnostic marker.

Materials and Methods

Ethics statement

All animal work was conducted under project licence numbers PPL 60/3712 and PPL60/4181 in accordance with accepted standards of humane animal care and according to the UK Animals (Scientific Procedures) Act 1986 and the EU directive 2010 in dedicated facilities proactive in environmental enrichment. Ethical approval granted by University of Glasgow.

Mammary gland preparation

The 4th (inguinal) mammary glands were dissected and used for immunohistochemical staining or RNA extraction as described previously [35]. Balb/C mice were used unless stated otherwise.

Cell Culture

KIM-2 cells were generated in the laboratory of C. Watson [36] and were maintained as previously described [36].

Anxa8 cloning into pRTS1

Anxa8 cDNA was cloned into the pRTS1 episomal vector [37], a generous gift from Prof Bornkamm, before generation of KIM-2 cell lines that express *Anxa8* under the control of doxycycline. To generate the pRTS1:*Anxa8* construct, the mouse cDNA of *Anxa8* was cut from the IMAGE clone 5322310 using the restriction enzymes XhoI and EcoRV and ligated into the pUC19-SfiI vector using the XhoI and EcoRV restriction sites. The resulting construct was digested with SfiI and the cDNA fragment ligated into the SfiI sites of the pRTS1 vector. Positive clones were confirmed by sequencing. KIM-2 cells were transfected using FuGene 6 (Roche Applied Science, Burgess Hill, UK) according to manufacturer's instructions with pRTS1:*Anxa8* and pRTS1 constructs and transfected cells were selected as pools using 250 μ g/ml of

hygromycin (Calbiochem, Merck KG, Darmstadt, Germany) to establish Kim2A8 and Kim2RTS cell lines.

Growth assay

Cells were plated in 24 well plates in triplicate and allowed to grow overnight before the addition of 100ng/ml doxycycline (Sigma-Aldrich, Gillingham, UK) at day 0. After washing the cells twice in PBS, protein lysates were prepared every 24 hours in Triton X-100 lysis buffer (20mM Tris pH 7.4, 250mM NaCl, 1% Triton X-100) plus Complete Mini Inhibitor mix (Roche Applied Science) and Protein Phosphatase Inhibitor Cocktail 2 (Sigma-Aldrich), and stored at -20°C . The protein concentration was measured using a BCA Protein Assay (Pierce, Thermo Fisher Scientific Inc, Rockford, USA).

BrdU/EdU incorporation assay

Proliferation was measured using a Cell Proliferation ELISA, BrdU colourimetric kit (Roche Applied Science) in a 96 well format after 48 hours of doxycycline treatment (100ng/ml).

For *in vivo* EdU incorporation: C57Bl/6 mice were stud mated and allowed to lactate with standardized litter sizes of 5–6 for 7 days at which time forced involution was induced. The females were injected intra-peritoneally with 0.2ml of 5mg/ml EdU 2hr prior to sacrifice on day 4 after forced involution. For pre-pubertal samples EdU was injected in 3-week old females as above.

Colony formation assay

Between 250 and 300 cells were seeded each in 10cm culture dishes in medium containing no doxycycline or 100ng/ml doxycycline. Cells were allowed to adhere and grow for 2 weeks, fixed with methanol, air dried and stained using Giemsa's staining solution (BDH Laboratory Supplies, Merck Ltd., Lutterworth, UK). Pictures of the plates were taken using a digital camera and the number of colonies was quantified using ImageJ software.

Cell cycle analysis by flow cytometry

Cells were grown in 6-well plates and treated with 100ng/ml doxycycline for 48 hours, trypsinized with Trypsin-EDTA, and collected together with any floating cells in the culture media. The cells were resuspended in 0.5ml PBS and fixed in 5ml 100% ice-cold methanol while vortexing. Cells were incubated for two hours at 4°C . After brief centrifugation, the methanol was removed and cells incubated in 400 μl PI solution (50 $\mu\text{g}/\text{ml}$ propidium iodide, 50 $\mu\text{g}/\text{ml}$ RNase A in PBS) for 30min before analysis on a BD FACSCanto II Flow Cytometer. Cyflogic software was used for analysis.

Antibody production

The mouse *Anxa8* coding region was amplified by PCR using the primers A8-5' (aatagaatt-caatggcctggtggaagcc) and A8-3' (cgatctcgagtcagaggtcagtgcccac) and the IMAGE clone 5322310 as template. The PCR fragment was digested with EcoR1 and XhoI, cloned into pET302NT His vector (Invitrogen, Paisley, UK) digested with the same restriction sites and sequenced to verify that the 6xHis tag was in frame and the *Anxa8* sequence was correct. This construct was used to produce ANXA8 protein in BL21 cells and the protein was purified using the TALON Metal Affinity Resin and Buffers (Clontech, Takara Bio Europe, Saint-Germain-en-Laye, France). After dialysis against PBS to remove imidazole, the purified protein was used to immunize two rabbits at EUROAGENTEC (Fawley, Southampton, Hampshire, UK), using

their standard protocol. The antiserum was affinity purified using recombinant His-tagged ANXA8 protein immobilized in a column generated using an AminoLink Plus Immobilisation Kit (Pierce). The antibodies were eluted from the column using 100mM glycine pH 2.5 and immediately neutralized by addition of 1/10 of the elution volume of 1M Tris. The specificity of the antibody was tested by western blot.

Immunofluorescence and Immunohistochemistry

Cells were grown on eight-well chamber slides for the indicated times and fixed in 4% paraformaldehyde for 20 min at RT. After extensive washes with PBS, cells were incubated for 10 min in 50mM ammonium chloride followed by incubation for 10 min in 20mM glycine. Cells were incubated for 30–45 min in blocking solution (2.5% horse serum in PBS, 0.3% Triton X-100) to prevent nonspecific binding. The primary and secondary antibodies were diluted in blocking solution and antibody incubations were carried out at RT for 45–60 min. Washes were done with 0.1% Triton X-100 in PBS. Cells were finally washed in PBS before mounting the slides using Prolong Gold Antifade Reagent with DAPI (Molecular Probes, Invitrogen). Images were taken using an Olympus IX51 inverted microscope using a F-View camera and Cell[^]P 2.5 software (Olympus UK Ltd, Southend-on-Sea, Essex, UK). ImageJ software was used for image analysis.

For immunofluorescence (IF) on paraffin-embedded tissue, the sections were dewaxed in xylene and rehydrated through an alcohol gradient. Antigen retrieval was performed in 10 mM EDTA pH 8.0, sections were treated with Image-iT FX (Molecular Probes) for 30 min at room temperature and blocked with 2.5% horse serum in TBS-0.01% Tween 20. Tissue sections were stained in the same way as cells except that TBS-Tween 20 was used instead of PBS. Rat anti Ki67 clone TEC3 staining was developed by sequential incubation with the biotinylated secondary antibody from the rat ABC Staining System (Santa Cruz Biotechnology, Santa Cruz, CA, USA) at 1:100 and Streptavidin Dylight 488 (Pierce) at 1:200.

For immunohistochemistry on paraffin-embedded tissues, sections were treated in the same way as for IF, without the Image-iT FX step and the staining was developed using the ImmPRESS Peroxydase System (Vector Labs, Peterborough, UK).

Primary antibodies were used at the following concentrations; rabbit anti-Annexin A8 (Eurogentec) 1:100 for tissue and cells; mouse anti-ER α clone 6F11 (Leica Microsystems, Milton Keynes, UK) 1:70; rat anti-Ki67 clone TEC-3 (Dako) 1:50; goat anti-MCM3 (G19, Santa Cruz) 1:300; goat anti-mouse SCF R/c-kit (AF1356, R&D Systems Inc., Minneapolis, MN, USA,) 1:100 for IF. Donkey Alexa Fluor 488- and Alexa Fluor 594-labelled secondary antibodies (Molecular Probes) were used at a dilution 1:1000. For triple-staining, donkey anti-rabbit Alexa Fluor 488, donkey anti-goat-Cy5, and donkey anti-rat-Cy3 antibodies were used.

For EdU staining, a Click-iT EdU Alexa Fluor 595 Imaging Kit was used as per manufacturer's instructions.

Western blotting

Protein extracts were prepared using Triton X-100 lysis buffer plus Complete Protease Inhibitors (Roche Applied Science) and Protein Phosphatase Inhibitor Cocktail 2 (Sigma-Aldrich). The proteins were separated in NuPAGE 4–12% Bis-Tris gels and transferred to PROTRAN nitrocellulose transfer membranes (Whatman, Springfield Mill, Maidstone, Kent, UK). Membranes were blocked in 3% BSA diluted in TBS-Tween (20mM Tris pH7.6, 137mM NaCl, 0.1% Tween-20). The antibodies were diluted in blocking solution and incubated with the membrane in agitation for 2 hours at room temperature or overnight at 4°C and washed with TBS-Tween before developing with ECL Western Blotting Detection Reagents (GE Healthcare,

UK Limited, Little Chalfont, Buckinghamshire, UK) in a FUJIFILM LAS-3000 Intelligent Dark Box (FUJIFILM UK Ltd, Bedford, UK). Antibodies were used at the following concentrations: rabbit anti-Annexin A8 (Eurogentec) 1:1000; rabbit anti-Ki67 (Abcam) 1:1000; goat anti-actin (C-11; Santa Cruz) 1:1000. Anti-goat secondary antibodies conjugated with horseradish peroxidase (DAKO, Glostrup Denmark) were used at 1:2000. Horseradish peroxidase-conjugated anti-rabbit IgG secondary antibody (GE Healthcare) was used at 1:5000.

Cell Sorting

Primary mouse mammary cells were isolated by mechanical and enzymatic digestion as described [38]. Single cell suspensions at 10^6 cells/ml were stained with anti-CD24-FITC (1.0 μ g/ml; BD Biosciences, Oxford, UK), anti-Sca-1-APC (1.0 μ g/ml; eBioscience, Hatfield, UK), anti-CD45-PE-Cy7 (1.0 μ g/ml; BD Biosciences), anti-CD49f-PE-Cy5 (5.0 μ l/ml; BD Biosciences) and anti-c-Kit-PE (1.0 μ g/ml; BD Biosciences). Cells were sorted on a FACSARIA (Becton Dickinson, Oxford, UK) and mammary stem cells (MaSCs; CD45⁻, CD24^{+/Low}, Sca-1^{neg}, CD49f^{High}, c-Kit⁻), myoepithelial cells (CD45⁻ CD24^{+/Low}, Sca-1⁻, CD49f^{Low}, c-Kit⁻), luminal epithelial ER α -ve progenitors (CD45⁻, CD24^{+/High}, Sca-1⁻, CD49f⁻, c-Kit⁺) and luminal epithelial ER α -ve differentiated cells (CD45⁻, CD24^{+/High}, Sca-1⁺, CD49f⁻, c-Kit⁻) isolated using sort gates and controls as described [39].

Freshly sorted normal cells were resuspended in RLT buffer (Qiagen, Crawley, West Sussex, UK) and stored at -80°C until required for RNA extraction. qPCR reactions were performed as previously described [40] using TAQMAN Assays-on-Demand probe for *Anxa8* (Mm00507926_m1). *Actb* (β -actin) was used as an endogenous control and results calculated using the $\Delta\Delta C_t$ method. Data were expressed as the fold difference in gene expression between the mean of three independently isolated cell preparations compared to control samples with 95% confidence intervals.

Quantitative RT-PCR on total mammary gland RNA

RNA from mammary glands was prepared using TRIZOL (Invitrogen) as described previously [35]. The RT reaction was carried out using 1 μ g of total RNA and Transcriptor reverse transcriptase (Roche Applied Science) following the guidelines of the supplier. For qPCR the following sets of primers and probes (Universal Probe Library from Roche Applied Science) were used to amplify *Anxa8* (ggaaaagcagcagacaggat, gagaactacccttcacgctgac, probe #31) and *Krt18* (agatgacaccaacatcacagg, tccagaccttggaactctc, probe #78) as internal control. The qPCR was performed using 1 μ l of cDNA as template, LC480 QPCR Master Mix (Roche Applied Science) and the appropriate set of primers in a 20 μ l reaction in a LightCycler 480 Instrument (Roche Applied Science).

Results

ANXA8 is expressed in a distinct subpopulation of luminal ductal epithelial cells

To obtain an indication towards ANXA8's role during mammary gland development it was necessary to assess its cellular distribution at different developmental time points. Since no antibodies were commercially available that recognised mouse ANXA8, a polyclonal antibody was raised and affinity-purified against full-length mouse ANXA8 protein, which showed specific reactivity in western blots with mouse ANXA8 but not with other annexins. Immunohistochemistry (IHC) detected ANXA8 protein specifically in a distinct subset of ductal luminal epithelial cells during puberty, adulthood, and pregnancy, and to a lesser extent in the major ducts during lactation (Fig. 1, S1 Fig.), while no ANXA8 was detectable in proliferating TEB or




Fig 1. ANXA8 protein expression during mammary gland development. Sections from pubertal (6 weeks; V6), virgin (12 weeks, V12) pregnant (P, days 4.5, 12.5, 17.5), lactating (day 7) and involuting mice (days 1, 2, 4, and 10) were stained for ANXA8 protein. Staining was detected in a distinct set of ductal luminal epithelial cells (arrows), while alveoli (arrowheads) did not stain for ANXA8. ANXA8 was not expressed in the

early involuting epithelium, but in the major ducts and widely in the surviving epithelium during late involution. The black bar represents 100 μ m.

doi:10.1371/journal.pone.0119718.g001

alveoli, or in differentiated alveolar epithelium. After enforced involution ANXA8 expression increased slowly and after four days was widely detected in major ducts and rarely in collapsed alveoli. After 10 days, ANXA8 was expressed in the majority of surviving ductal epithelial cells, which was consistent with the increased abundance of *AnxA8* mRNA observed by qRT-PCR post-involution (S2 Fig.). In summary, ANXA8 expression was associated with a subpopulation of luminal ductal epithelial cells and with the surviving ductal epithelium during involution.

ANXA8 expression is absent in highly proliferative mammary epithelium

Analysis of data from a previous microarray study of pre-pubertal, pubertal and post-pubertal mouse mammary glands revealed that *Anxa8* mRNA abundance was highest during pre-puberty and strongly reduced at the onset of puberty (Fig. 2 (A)) [41] when the non-proliferative rudimentary ducts form proliferative TEB that grow out into the surrounding fat pad to establish the primary ductal mammary epithelial network. This reduction was confirmed by




Fig 2. ANXA8 is expressed strongest during pre-puberty. (A) Microarray results from a previous microarray study [41], using RNA extracted from 3-, 4-, 5-, 6- and 7-week old CD1 mice, show a reduction in *AnxA8* mRNA at the onset of puberty. Signal intensities for two independent probes targeting *AnxA8* were normalised to cytokeratin 18 (Krt18) to eliminate changes due to differences in epithelial content. (B) qRT-PCR results for *AnxA8* normalised to Krt18 expression from RNA extracted from mammary glands of 3-, 4-, 6-, and 12-week-old mice. (C-D) Immunohistochemical analysis of ANXA8 expression using the E2R6.2 antibody on mammary glands from 3- (C) and 6-week old (D) mice showing staining for ANXA8 in the pre-pubertal rudiment and in ducts, but not TEB, of pubertal mice. Negative control (–ve ctrl): no primary antibody. Bars represent 100 μ m.

doi:10.1371/journal.pone.0119718.g002

qRT-PCR using mRNA from 3-, 4-, 6-, and 12-week old mice, when normalised to the epithelial cell marker CK18 (Fig. 2(B)). IHC analysis showed again that ANXA8 was expressed in a distinct subpopulation of luminal epithelial cells of the pre-pubertal rudimentary epithelium (Fig. 2 (C)), as well as in individual cells of the ductal luminal epithelium in pubertal glands but never in TEB (Fig. 2 (D)). In contrast, Ki67 expression was widespread in TEB and in proliferating alveoli during pregnancy but rare in major ducts (S3 Fig.). ANXA8's association with non-proliferative cells was further emphasised when 3-week old mice were injected with EdU for two hours (S4 Fig. (A)). Mammary glands from three independent mice showed no co-staining for ANXA8 and EdU. Highly proliferative regions, possibly by the onset of puberty, showed strong EdU staining, but no ANXA8 positivity, while ANXA8+ve ducts showed little EdU positivity with no overlap. Similar results were found in 4-day involuting glands, where strong ANXA8 staining but no EdU staining was observed in the surviving ductal epithelium (S4 Fig. (B)). Our results therefore associate ANXA8 with the low-proliferative rudimentary ductal epithelium, and show that its expression is switched off during pubertal outgrowth and proliferation.

ANXA8 expressing epithelial cells are ER α -ve and transiently quiescent

Double-immunofluorescent (IF) labelling of pubertal mammary sections for ANXA8 and Ki67 established that over 99% of ANXA8+ve cells were quiescent with a lack of Ki67 expression (Fig. 3 (A, B)) and of the licensing factor MCM3 (S5 Fig.). However, the proportion of Ki67+ve/ANXA8+ve cells increased significantly during early pregnancy, reaching ~15% of all ANXA8+ve cells (compared to ~20% in ANXA8-ve ductal cells) but decreasing again to ~5% during mid-pregnancy (day 12.5), while the proportion of cycling ANXA8-ve cells remained constantly high (~19%; Fig. 3(B)). This demonstrated that ANXA8+ve cells were not all terminally differentiated, but were able to enter the cell cycle at the start of ductal budding, though ANXA8 was not detected in the newly formed epithelial structures.

Since it has previously been reported that ER α -ve cells of the mammary epithelium are the main proliferative compartment, the ER α -status of the ANXA8+ve cells was also established. Double-IF staining demonstrated that all ANXA8 expressing cells were in fact ER α -ve (Fig. 3 (C, D)), showing that ANXA8 was associated with a transiently quiescent ER α -ve subpopulation.

AnxA8 mRNA is associated with c-kit+ve/ER α -ve luminal progenitor cells

ANXA8 is strongly expressed in BRCA1-associated breast cancers and these cancers have recently been shown to originate from ER α -ve luminal progenitor cells [42]. Since ANXA8 showed strong association with ER α -ve cells in the mammary gland it was hypothesised that ANXA8 was associated with the ER α -ve progenitor cell population. *AnxA8* mRNA expression was therefore measured by qRT-PCR in RNA from mammary epithelial cells that had been sorted according to their expression of the cell surface proteins CD24, CD49f, Sca1, and c-kit: a) mammary stem cells (MaSC; CD24^{+/low}, Sca1⁻, CD49f^{+/high}, c-kit⁻), b) myoepithelial cells (CD24^{+/low}, Sca1⁻, CD49f^{+/low}, c-kit⁻), c) mature luminal ER α +ve cells (CD24^{+/high}, Sca1⁺, CD49f⁻, c-kit⁻), and ER α -ve luminal progenitor cells (CD24^{+/high}, Sca1⁻, CD49f⁻, c-kit⁺) [39]. While no *AnxA8* mRNA was detectable in MaSC or myoepithelial cells, the luminal ER α -ve progenitor cell population had a 17-fold increased abundance compared to the differentiated luminal ER α +ve population (Fig. 4 (A)). The strong association of ANXA8 and c-kit expression was further emphasised by IF (Fig. 4 (B, C)). ANXA8 was co-expressed with c-kit in the luminal epithelium of mammary ducts, and localised to the cytoplasm as well as the apical and, similar to c-kit, to the lateral membranes (Fig. 4 (C)). However, co-expression of c-kit and




Fig 3. ANXA8 positive cells are ER α and Ki67 negative. Co-immunofluorescence staining for ANXA8 and Ki67 (A) or ER α (C) in 6-week old mice shows that those cells strongly positive for ANXA8 are negative for ER α and Ki67. Graphs represent the mean percentage of ANXA8 positive and negative cells that are positive or negative for Ki67 (B) or ER α (D) based on 1,000 cells per developmental time point (B) and at least 500 cells (D). V6: virgin 6 weeks; P4.5: pregnancy day 4.5; P12.5: pregnancy day 12.5. Error bars denote standard error of the mean.

doi:10.1371/journal.pone.0119718.g003

ANXA8 varied within and between sections. While all ANXA8+ve cells were c-kit+ve independent of developmental stage, ANXA8 positivity of c-kit+ve cells ranged from as little as 0% to 100%. During puberty, strong c-kit staining was detected in the inner body cells of the TEB




Fig 4. ANXA8 is expressed in ER α -ve/c-kit+ve luminal progenitor cells. (A) Primary mammary epithelial cells were sorted and RNA extracted as described previously [39]. qRT-PCR was used to measure *AnxA8* mRNA abundance in four different populations. *AnxA8* was not detected in either mammary stem cells (MaSC) or myoepithelial cells. Although very low levels were detected in differentiated ER α +ve luminal epithelial cells, ER α -ve luminal epithelial progenitor cells showed a 17-fold higher abundance. The graph shows the abundance relative to the levels of expression in differentiated cells and 95% confidence limits. (B) Bar graph showing the proportion of c-kit+ve/*AnxA8*+ve and c-kit+ve/*AnxA8*-ve cells during puberty (V6), early (P4.5) and late (P12.5) pregnancy. 1,000 cells were assessed per developmental time point. Error Bars denote standard error of the mean. (C) Co-immunofluorescence staining for ANXA8 and c-kit in mouse mammary gland from an early-pregnant (day 4.5) mouse.

doi:10.1371/journal.pone.0119718.g004

while ANXA8 could only be found in the ductal epithelium (S6 Fig.). During pregnancy ANXA8 and c-kit expression were both restricted to the ductal epithelium, though limited c-kit staining was found in the newly formed ductal outgrowth. The percentage of ANXA8+ve/c-kit+ve positive cells was reduced during pregnancy from just ~62% to ~34% (Fig. 4 (B)), possibly reflecting the overall reduction in ANXA8+ve cells as c-kit was still expressed in the majority of ductal luminal epithelial cells.

Triple-staining of mammary glands from pubertal and mid-pregnant mice further confirmed that ANXA8+ve/c-kit+ve cells were mostly Ki67–ve (Fig. 5). Our results therefore strongly suggest that ANXA8 is associated with a subpopulation of mostly quiescent c-kit+ve/ER α –ve ductal luminal progenitor cells.

ANXA8 over expression reduces proliferation in Kim-2 cells

Since ANXA8 expression was associated with low proliferation in the mammary gland and other tissues [43,44], *in vitro* studies were carried out to assess whether ANXA8 could directly affect cell proliferation. Mouse ANXA8 was over expressed in the mouse mammary epithelial cell line Kim-2, using an inducible episomal vector under the control of doxycycline (dox) (Kim2A8). Approximately 50% of the pooled cells expressed ANXA8 and EGFP through a bi-directional promoter when treated with 100ng/ml dox (S7 Fig.). Since only EGFP-positive cells expressed ANXA8, EGFP-positivity was used as a surrogate marker for ANXA8 expression in further experiments.

Microscopic analysis after dox-treatment showed that after two days the EGFP+ve cells were increased in size (Fig. 6 (A)) compared to EGFP–ve cells, and after six days showed a highly enlarged and flattened morphology (Fig. 6 (B)) with significantly enlarged nuclei (Fig. 6 (C)). Although this morphology was reminiscent of senescent cells, the cells were negative for the senescence markers β -galactosidase (β -gal) and p16 (data not shown).

A cell growth assay of Kim2A8 cells showed that after three days of dox-treatment Kim2A8 cell growth was significantly reduced compared to control cells (Fig. 7 (A)). Since the decreased growth rate was associated with reduced BrdU incorporation (Fig. 7 (B)) our results showed that in this system ANXA8 over-expression was able to reduce cell proliferation.

ANXA8 over expression prevents colony formation of Kim-2 cells *in vitro*

To further characterise the effect of ANXA8 over expression on cell proliferation, a 2D colony formation assay was performed. Kim2A8 and control cells were seeded as single cell suspensions and treated with or without dox. Colonies were analysed by bright-field and fluorescence microscopy. After two weeks of dox-treatment Kim2A8 cells formed significantly fewer colonies of more than 50 cells compared to untreated Kim2A8 cells or control cells (Fig. 7 (C, D)). All large colonies that formed from the dox-treated Kim2A8 cells were largely EGFP–ve (with the occasional entrapped green cell), and hence did not express ANXA8. EGFP+ve cells remained either as single cells or very small colonies of <10 cells, and showed again the above mentioned enlarged morphology (S8 Fig.).

ANXA8 over expression induces quiescence in Kim-2 cells

FACS analysis was performed after 48 hours with or without dox-treatment to further assess the nature of the growth arrest induced by ANXA8 expression in Kim2A8 cells (Fig. 8 (A)). Dox-treated Kim2A8 cells showed a significantly higher proportion of cells in G₀/G₁ (75%) compared to untreated Kim2A8 cells (59%) or the negative control cells (52% –dox; 54%+dox), while the amount of Kim2A8 cells in S- or G₂/M-phase was strongly reduced (S-phase: –dox: 16%; +dox:<8%; G₂/M: –dox:23% vs +dox:15%), demonstrating an arrest at G₀/G₁. No increase




Fig 5. ANXA8+ve/c-kit+ve luminal progenitor cells are mostly Ki67–ve. Co-immunofluorescence staining for ANXA8 (green), c-kit (red), and Ki67 (purple) in mouse mammary gland from virgin and mid-pregnant mice shows that ANXA8+ve cells express c-kit, but not Ki67. The Ki67 staining has been coloured purple for easier visualisation in the triple-merged image. These are representative images of at least three independent mice for each time point.

doi:10.1371/journal.pone.0119718.g005





Fig 6. ANXA8 expression induces morphological changes in Kim-2 cells. Kim2A8 and Kim2RTS cells were grown in the presence or absence of 100ng/ml dox. Pictures were taken after 48 hours (A) or six days (B) of treatment. EGFP was used as a reporter of ANXA8 expression. Both proteins are expressed from opposite sides of a bidirectional promoter. (C) Nuclear sizes were analysed after 6 days by measuring the nuclear area (stained with DAPI) of at least 90 individual cells from each dox-treated and untreated populations using ImageJ. There was a significant difference between Kim2A8 cells expressing and not expressing ANXA8 (ANOVA: $p < 0.05$).

doi:10.1371/journal.pone.0119718.g006




Fig 7. ANXA8 expression inhibits proliferation of Kim2A8 cells. (A) Kim2A8 and Kim2RTS cells were seeded in 24-well plates, allowed to attach and grown in the presence or absence of 100ng/ml dox (first treatment at time point 0). At each time point protein extracts were prepared (in duplicates). The graph shows the amount of protein as determined by BCA assay against time. This assay was performed in triplicate and the graph shows a representative result from one experiment. (B) Cells were seeded in 96-well plates and treated with dox for 48 hours, labelled with BrdU and the incorporation of BrdU was quantified and plotted for each condition (six wells per condition). *** $p < 0.001$ (C) Equal amount of cells (250–300) were grown in the presence or absence of 100ng/ml dox. After 14 days cells were fixed, stained and the plates photographed. A representative plate per condition is shown. The experiment was carried out in triplicate. (D) Graph showing the number of colonies per plate from the experiment (C) as quantified by Image J (** $p < 0.003$).

doi:10.1371/journal.pone.0119718.g007




Fig 8. ANXA8 expression arrests Kim2A8 cells in G₀. (A) Kim2A8 and Kim2RTS cells were grown in 6-well plates with or without 100ng/ml of dox for 48 hours. The graph shows the average percentage numbers of cells in G₀/G₁, S and G₂/M as quantified by FACS from three independent experiments. (B)

Kim2A8 and Kim2RTS cells grown in chamber slides with or without 100ng/ml dox for six days were fixed and stained for Ki67 antigen. EGFP was used as a reporter of ANXA8 expression. (C) Graph showing the percentage of Ki67-positivity in the EGFP positive and negative populations of Kim2A8 cells grown with or without 100ng/ml dox. At least 1000 cells were analyzed in each population. (D) Western blot showing Ki67 and ANXA8 protein expression in cells after six days in culture. Actin was used as a loading control. Numbers show the relative intensities of ANXA8 and Ki67 bands respectively (normalised to actin) determined by measuring area pixel intensities using AIDA Image Analyzer software. The reduction of Ki67 levels (~50%) is consistent with the reduced number of Ki67+ve Dox-treated Kim2A8 cells seen in (B).

doi:10.1371/journal.pone.0119718.g008

in the sub-G₀/G₁ fraction was observed (all between 1–1.5%), confirming that ANXA8 over expression did not induce cell death.

To establish whether ANXA8 over expressing cells were arrested in G₁ or entered G₀, we measured Ki67 expression levels by IF staining (Fig. 8 (B, C)) and western blot (Fig. 8 (D)). IF staining showed that only ~50% of EGFP-positive Kim2A8 cells expressed Ki67, while nearly all EGFP negative cells, like the control cells, were Ki67 positive (~95%; $p < 0.003$). In western blots untreated cells and dox-treated control cells showed similar levels of Ki67 protein, while over expression of ANXA8 for 6 days significantly reduced Ki67 protein levels by ~50%. This demonstrated that ANXA8 over expression had taken KIM-2 cells out of the cell cycle.

Discussion

We previously described *Anxa8* mRNA to be expressed in isolated mammary ducts and after enforced involution, but not during pregnancy and lactation when primary ducts branch and bud to form milk secreting alveoli [45]. The current study further defines ANXA8 expression in a mostly quiescent subpopulation of c-kit+ve/ER α -ve progenitor cells of the ductal epithelium, and identifies ANXA8 as a potential regulator of proliferation and/or quiescence in the mouse mammary ductal epithelium. No significant levels of *Anxa8* expression were found in ER α +ve cells, or in differentiated alveoli of late pregnant or lactating mice (Figs. 1, and 3), showing that ANXA8 expression was not associated with terminal differentiation of the mammary epithelium. Instead, ANXA8 was only present in the major ducts, which bud during pregnancy to form alveoli, and was widespread in the ducts of a late involuting gland, when apoptosis had ceased and the primary mammary ductal system was regenerating.

Although a large proportion of c-kit+ve cells showed ANXA8 expression by double-IF staining, not all of them did, and as ANXA8 and Ki67 staining were largely exclusive it appears that ANXA8 may be characteristic of a mostly quiescent subpopulation of committed ER α -ve progenitor cells, which our triple-staining supports. However, rare Ki67+ve/ANXA8+ve cells could be detected (less than 1% of all ANXA8+ve cells) during puberty and this proportion increased at the start of pregnancy, but decreased again with prolonged pregnancy while Ki67 staining of ductal ANXA8-ve cells remained increased. Therefore, although ANXA8 expressing cells were mostly quiescent, these cells were not terminally differentiated. It is unclear whether the progeny of the ANXA8+ve cells contribute to the formation of side branches and alveoli. No ANXA8 staining was found in alveoli and c-kit staining was equally down-regulated. Though *Anxa8* mRNA was recently detected in quiescent normal human mammary stem cells isolated from mammosphere cultures on the basis of PKH26-retention [46], we could not detect ANXA8 in mouse mammary stem cells. An association with very early mammary epithelial progenitor cells is supported by the recent finding that *Anxa8* mRNA is expressed in the early developing mammary bud epithelium (E12.5) which showed limited proliferation and expressed c-kit [47], though in contrast to c-kit we were not able to detect ANXA8 protein by IHC at this time point (data not shown).

A recent finding that ANXA8 is part of the ADAM-17/AREG shedding complex and can modulate the shedding of pro-amphiregulin and other EGF family members on the cell surface [48], and the finding that ANXA8 affects ligand-induced degradation of EGFR [31] raises the

attractive possibility that ANXA8 may directly affect ligand availability for growth factor receptors and/or signalling, thereby controlling cell growth and/or differentiation. Since ADAM17 has also been shown to be a major sheddase for c-kit [49] and growth factor ligands including kit-ligand [50] it is tempting to speculate that ANXA8 may directly affect c-kit signalling in the luminal progenitors of the mammary gland. It was also noticeable that the number of ANXA8 positive cells varied greatly between ductal areas in a gland and between glands of similar time points. Whether ANXA8+ve cells mark the sites of future secondary/tertiary branches is currently subject of further investigations using a lineage tracing approach.

Our current data are further consistent with other studies that have linked *Anxa8* expression to reduced proliferative activity and/or quiescence. When quiescent NIH3T3 fibroblasts were driven into proliferation by transduction with an adenoviral E2F1 construct *Anxa8* was one of the strongest down-regulated genes in two independent experiments [51]. Similar results for *Anxa8* were obtained when NIH3T3 cells were transfected with Nanog, leading to increased proliferation and transformation and a reduction in *Anxa8* mRNA [52]. In the fetal bovine growth plate ANXA8 expression forms a gradient in which the higher expression is found in the low-proliferative hypertrophic zone [44], while in adult mouse stratified epithelia ANXA8 is expressed in supra-basal layers, suggesting that ANXA8 expression may be associated with partial differentiation [43], though our own studies identified ANXA8 in Ki67-ve cells of the basal layer (data not shown). Further, since ANXA8 expression was not detected in differentiating alveolar cells during pregnancy or lactation it is highly unlikely to be associated with differentiation in the mammary gland.

Despite *Anxa8* mRNA up-regulation early during involution, ANXA8 protein could not be detected in the early collapsing alveoli and therefore was unlikely to be involved in apoptosis, as our microarray profile may have suggested. Involution can be induced through forced weaning of the pups at the height of lactation, leading to widespread alveolar cell death and tissue remodeling, after which the mammary gland resembles a pre-pregnant-like mammary gland. Transcriptional microarray profiling identified *Anxa8* mRNA to be strongly increased 24 hours after enforced mammary gland involution with sustained abundance for several days [29], though our qRT-PCR data now show a much slower increase. Similar increases can be found for c-kit and the kit ligand SCF (S9 Fig.), indicating that the involution recovery involves c-kit+ve progenitor cells and/or leads to a relative increase in c-kit+ve cells due to a preferential loss of differentiated alveolar cells. ANXA8 protein was not detected in the apoptotic alveoli 48 hours after enforced weaning (Fig. 1, S1 Fig.), but was detectable in major ducts and in most of the surviving epithelium after 10 days. Neither could ANXA8 be found in TEB during puberty where apoptosis is prevalent during ductal lumen formation [53,54]. Our view that ANXA8 is not associated with cell death is further supported by our finding that ANXA8 over expression in Kim-2 cells did not induce cell death, as indicated by no change in the sub-G₁ fraction after ANXA8 over expression (Fig. 8). There was though some expression of ANXA8 in the collapsed epithelial structures 4 days after forced weaning when most apoptosis has already ceased and tissue remodeling with an immune response and suppressed inflammation occurs [35,55,56]. It cannot be ruled out that ANXA8 expression in these structures may be associated with its PLA₂ inhibitory activity described for many annexins, including ANXA8 [17], thereby supporting the inflammatory suppression described previously [35,56].

Several annexins, including annexins A1 [10,57], A2 [58,59] and A6 [60,61] have been found to modulate proliferation or to be directly involved in cell division, including annexin A11, which is part of and necessary for midbody formation during cytokinesis [5]. Inhibition of proliferation induced by ANXA1 and ANXA6 correlated with concomitant changes in the actin cytoskeleton and cell morphology. ANXA8 has previously been found to interact with F-actin in co-sedimentation assays and with PIP₂, suggesting that ANXA8 may play a role in the

regulation of actin/membrane interactions [62]. However, we did not detect any changes in the actin cytoskeletal structure in Kim2A8 cells (data not shown). The morphological changes we observed were similar to those reported for ANXA2 over-expression in MIO Müller cells [63], in which ANXA2 expression induced the cells to become flattened, but the increase in the size of the footprint observed did not correlate with an increase in cellular volume when analysed by FACS. It has also been demonstrated that over expression of ANXA8 in SCK, MDA-MB231 and NIH3T3 cells can induce morphological changes, inducing a more epithelial-like morphology, and that these changes may be mediated through direct interaction of ANXA8 with FAK [23].

ANXA8's reduced expression in the majority of breast cancers is consistent with an anti-proliferative role of ANXA8. However, the finding that positive staining correlates with basal-like breast cancers that are of high grade and positive for Ki67 [29] is somewhat counterintuitive. Similar results have been described for the tumour suppressor protein p16/INK4, which is associated with cell cycle arrest and senescence, but is strongly associated with basal-like breast cancers [64]. Further, the cell cycle protein cyclin E has been shown to induce cell cycle arrest by p27KIP accumulation in mammary epithelial cell lines HC-11 and 184B5, though it increased proliferation in others [65,66] and is strongly expressed in basal-like breast cancers [67]. Since c-kit+ve/ER α -ve luminal progenitor cells have recently been shown to be the origin of basal-like breast cancers [42,68], and since ANXA8 is strongly associated with this subgroup, it is possible that ANXA8 expression in these cancers is a reflection of ANXA8's close association with luminal progenitor cells, and that the pro-quiescence function of ANXA8 might be perturbed. A similar association of ANXA8 with committed human progenitor cells and cancer had previously been found in the haematopoietic system, where *Anxa8* mRNA expression was detected in pro-myelocytes and was further up-regulated in APL [69], a leukaemia in which the c-kit+ve progenitor cell population is abnormal and expanded. *Anxa8* was specifically up-regulated in APL but not in other myelocytic leukaemias [18,19,69]. Treatment with ATRA down-regulated ANXA8 expression and pushed cells into differentiation [19]. Though a causal link between ANXA8 down-regulation and differentiation of APL cells has not been tested it is tempting to speculate that ANXA8 might be involved in progenitor cell maintenance. Further studies will reveal whether the same association exists between the ANXA8+ve cells of the terminal duct lobular unit [29] and c-kit in the human breast.

Given our results and the association of ANXA8 expression with ER-ve breast cancers it will be worth testing whether ANXA8 over-expression in ER+ve breast cancer cell lines can induce cellular quiescence or reduce proliferation. However, as the human genome contains at least two *Anxa8* genes (*Anxa8*, *Anxa8l1*), which vary slightly in their encoding sequence, and in the absence of promoter expression studies, epigenetic analyses and human genotyping, it is impossible to know which one (if not both) of these genes contributes to the variations observed in gene expression in the normal and malignant breast. The existence of copy number and allelic population variants could further affect gene product "dosage" as well as the pharmacogenetic responsiveness of these genes [70]. Therefore, over-expression of each variant on its own and in combination in a variety of breast cancer cell lines will be necessary.

Conclusion

We have established for the first time that ANXA8 expression is associated with a subpopulation of transiently quiescent c-kit+ve/ER α -ve cells of the ductal epithelium and that ANXA8 over expression can induce quiescence *in vitro*. The mechanism(s) by which ANXA8 induces this G₀-arrest is still unknown. Its expression is therefore strongly associated with a luminal epithelial progenitor cell population that is thought to be the origin of basal-like breast cancers, a

subgroup of breast cancers with which ANXA8 is strongly associated. Further work will establish whether ANXA8 is functionally involved in progenitor cell quiescence and/or maintenance, and whether ANXA8 positive mammary epithelial cells may be the origin of ANXA8-expressing basal-like breast cancers.

Supporting Information

S1 Fig. ANXA8 protein expression during mammary gland development. Close-up view of images from [Fig. 1](#). The black bar represents 100µm.
(TIF)

S2 Fig. qRT-PCR results for Anxa8 from 13 stages of mammary gland development. Total RNA was extracted from mammary glands at the indicated time points and tested for presence of Anxa8 mRNA by qRT-PCR. Results are shown in relation to Krt 18 mRNA abundance.
(TIF)

S3 Fig. ANXA8 and Ki67 expression in TEB, ducts, and during early pregnancy. Immunohistochemical staining for ANXA8 and Ki67 of consecutive mammary tissue sections of the same TEB and duct region from the same 3-, and 5-week C57BL/6 old pubertal mice, and from an early pregnant mouse (day 4.5) shows that areas of ANXA8 and Ki67 expression are largely exclusive. Magnification x100.
(TIF)

S4 Fig. ANXA8 expression in EdU labelled mammary glands. Double-immunofluorescent labelling for ANXA8 (green) and EdU (red) shows that ANXA8+ve cells are EdU–ve in pre-puberty and during involution. Mouse mammary glands have been *in vivo* labelled for 2 hours in pre-pubertal mice (3 weeks of age) (A), and 4 days after forced weaning (B) before culling. (A) Top two rows show examples of mammary ducts with high ANXA8-staining but little EdU staining in the mammary epithelium, while the bottom row shows a typical TEB with high EdU-staining but no ANXA8 staining. (B) At 4 days of involution mammary glands showed no epithelial EdU incorporation, but widespread ANXA8 expression. Top two rows show two epithelial ducts, while the bottom row shows positive EdU staining in lymphocytes of the inguinal lymph node (pos. control). Bars represent 50µm.
(TIF)

S5 Fig. ANXA8 positive cells are negative for MCM3. Co-immunofluorescence staining for ANXA8 and MCM3 in 6-week old C57BL/6 mice shows that those cells strongly positive for ANXA8 are MCM3–ve. Bars represent 50µm.
(TIF)

S6 Fig. Co-expression of ANXA8 and c-kit protein. Co-immunofluorescence staining for ANXA8 (red), and c-kit (green) in a mouse mammary gland from a 6-week old virgin (V6) and a 12-day pregnant (P12.5) adult mouse showing that while all ANXA8+ve cells express c-kit, only a subgroup of c-kit+ve cells express ANXA8. Bars represent 50µm.
(TIF)

S7 Fig. Kim2A8 cells express ANXA8 and EGFP after dox induction. (A) Kim2A8 cells were grown in chamber slides with 100ng/ml dox for 24 hours, fixed and stained with E2R6.2 antibody to detect ANXA8 expression. EGFP was co-expressed by a bi-directional promoter. All EGFP positive cells expressed ANXA8, so that EGFP positivity could be used as a reporter for ANXA8 expression in this cell line. (B) Kim2A8 and Kim2RTS cells were grown in the presence of 100ng/ml of dox for 5 days and ANXA8 protein levels measured in dox-treated and

un-treated cells. Actin was used as a loading control.
(TIF)

S8 Fig. Colony formation of ANXA8 over-expressing Kim2 cells is suppressed. Kim2A8 cells were grown for two weeks in the presence of 100ng/ml dox as described in Fig. 7(C). Single cells or small colonies (<20 cells) of EGFP-positive Kim2A8 cells were detected after two weeks of growth. These cells showed a flat, large and round morphology. Images of typical colonies from Kim2A8 cells with or without dox treatment are shown.
(TIF)

S9 Fig. RNA expression of *c-kit*, *SCF* and *AnxA8* during enforced involution. Microarray results from lactating (day 7) and involuting (days 1, 2, 3, 4, 20) mouse mammary glands from a previous study [35]. The graphs show the normalized average signal intensities for *AnxA8*, *c-kit*, and *scf/kit ligand* mRNAs \pm standard error.
(TIF)

Acknowledgments

The authors would like to thank Prof Barry Gusterson for helpful advice, financial support and critical discussions. They would also like to thank Drs J. Stingl, A. Michie, C. Huser, E. Cosimo, D. Olijnyk, Mr J. Kennedy and Ms M. Vukovic for technical assistance as well as helpful discussions and advice. Further, they would like to thank Prof. C. Watson for the Kim-2 cell line and Dr. B. Howard for providing embryonic mammary bud sections.

Author Contributions

Conceived and designed the experiments: JMI MJS TS KB. Performed the experiments: JMI CJC RKF LM KS HK MAP TS. Analyzed the data: JMI KS HK MJS KB TS. Contributed reagents/materials/analysis tools: JMI FM MJS KB TS. Wrote the paper: JMI ROM TS.

References

1. Morgan RO, Martin-Almedina S, Garcia M, Jhoncon-Kooyip J, Fernandez MP. Deciphering function and mechanism of calcium-binding proteins from their evolutionary imprints. *Biochim Biophys Acta*. 2006; 1763: 1238–1249. PMID: [17092580](#)
2. Liu J, Vishwanatha JK. Regulation of nucleo-cytoplasmic shuttling of human annexin A2: a proposed mechanism. *Mol Cell Biochem*. 2007; 303: 211–220. PMID: [17457518](#)
3. Lin CY, Jeng YM, Chou HY, Hsu HC, Yuan RH, et al. Nuclear localization of annexin A1 is a prognostic factor in oral squamous cell carcinoma. *J Surg Oncol*. 2008; 97: 544–550. doi: [10.1002/jso.20992](#) PMID: [18297688](#)
4. Rick M, Ramos Garrido SI, Herr C, Thal DR, Noegel AA, et al. Nuclear localization of Annexin A7 during murine brain development. *BMC Neurosci*. 2005; 6: 25. PMID: [15819996](#)
5. Tomas A, Futter C, Moss SE. Annexin 11 is required for midbody formation and completion of the terminal phase of cytokinesis. *J Cell Biol*. 2004; 165: 813–822. PMID: [15197175](#)
6. Hayes MJ, Rescher U, Gerke V, Moss SE. Annexin-actin interactions. *Traffic* 2004; 5: 571–576. PMID: [15260827](#)
7. Moss SE, Morgan RO. The annexins. *Genome Biol*. 2004; 5: 219 PMID: [15059252](#)
8. Morgan RO, Martin-Almedina S, Iglesias JM, Gonzalez-Florez MI, Fernandez MP. Evolutionary perspective on annexin calcium-binding domains. *Biochim Biophys Acta*. 2004; 1742: 133–140. PMID: [15590063](#)
9. Rescher U, Gerke V. Annexins—unique membrane binding proteins with diverse functions. *J Cell Sci*. 2004; 117: 2631–2639. PMID: [15169834](#)
10. Ang EZ-F, Nguyen HT, Sim H-L, Putti TC, Lim LHK. Annexin-1 regulates growth arrest induced by high levels of estrogen in MCF-7 breast cancer cells. *Mol Cancer Res*. 2009; 7: 266–274. doi: [10.1158/1541-7786.MCR-08-0147](#) PMID: [19208747](#)

11. Raynal P, Pollard HB, Srivastava M. Cell cycle and post-transcriptional regulation of annexin expression in IMR-90 human fibroblasts. *Biochem J.* 1997; 322 (Pt 2): 365–371.
12. Schlaepfer DD, Haigler HT. Expression of annexins as a function of cellular growth state. *J Cell Biol.* 1990; 111: 229–238. PMID: [2142163](#)
13. de Graauw M, van Miltenburg MH, Schmidt MK, Pont C, Lalai R, et al. Annexin A1 regulates TGF-beta signaling and promotes metastasis formation of basal-like breast cancer cells. *Proc Natl Acad Sci U S A.* 107: 6340–6345. doi: [10.1073/pnas.0913360107](#) PMID: [20308542](#)
14. Fatimathas L, Moss SE. Annexins as disease modifiers. *Histol Histopathol.* 2010; 25: 527–532 PMID: [20183805](#)
15. Hayes MJ, Moss SE. Annexin 2 has a dual role as regulator and effector of V-Src in cell transformation *J Biol Chem.* 2009; 284: 10202–10210. doi: [10.1074/jbc.M807043200](#) PMID: [19193640](#)
16. Gonzalo DH, Lai KK, Shadrach B, Goldblum JR, Bennett AE, et al. Gene expression profiling of serrated polyps identifies annexin A10 as a marker of a sessile serrated adenoma/polyp. *J Pathol.* 2013; 230: 420–429. doi: [10.1002/path.4200](#) PMID: [23595865](#)
17. Hauptmann R, Maurer-Fogy I, Krystek E, Bodo G, Andree H, et al. Vascular anticoagulant beta: a novel human Ca²⁺/phospholipid binding protein that inhibits coagulation and phospholipase A2 activity. Its molecular cloning, expression and comparison with VAC-alpha. *Eur J Biochem.* 1989; 185: 63–71. PMID: [2530088](#)
18. Chang KS, Wang G, Freireich EJ, Daly M, Naylor SL, et al. Specific expression of the annexin VIII gene in acute promyelocytic leukemia. *Blood.* 1992; 79: 1802–1810. PMID: [1313714](#)
19. Hu ZB, Ma W, Uphoff CC, Drexler HG. Expression and modulation of annexin VIII in human leukemia-lymphoma cell lines. *Leukemia Res.* 1993; 17: 949–957. PMID: [8231235](#)
20. Liu JH, Stass SA, Chang KS. Expression of the annexin VIII gene in acute promyelocytic leukemia. *Leukemia Lymphoma.* 1994; 13: 381–386. PMID: [8069182](#)
21. Sarkar A, Yang P, Fan YH, Mu ZM, Hauptmann R, et al. Regulation of the expression of annexin VIII in acute promyelocytic leukemia. *Blood.* 1994; 84: 279–286. PMID: [8018923](#)
22. Karanjawala Z, Illei P, Ashfaq R, Infante J, Murphy K, et al. New Markers of Pancreatic Cancer Identified Through Differential Gene Expression Analyses: Claudin 18 and Annexin A8. *Am J Surg Pathol.* 2008; 32: 188–196. doi: [10.1097/PAS.0b013e31815701f3](#) PMID: [18223320](#)
23. Lee M-J, Yu G-R, Yoo H-J, Kim J-H, Yoon B-I, et al. ANXA8 Down-regulation by EGF-FOXO4 Signaling Is Involved in Cell Scattering and Tumor Metastasis of Cholangiocarcinoma. *Gastroenterology.* 2009; 137: 1138–1150. doi: [10.1053/j.gastro.2009.04.015](#) PMID: [19376120](#)
24. Singhal S, Wiewrodt R, Malden LD, Amin KM, Matzie K, et al. Gene expression profiling of malignant mesothelioma. *Clin Cancer Res.* 2003; 9: 3080–3097. PMID: [12912960](#)
25. Jaeger J, Koczan D, Thiesen H-J, Ibrahim SM, Gross G, et al. Gene expression signatures for tumor progression, tumor subtype, and tumor thickness in laser-microdissected melanoma tissues. *Clin Cancer Res.* 2007; 13: 806–815. PMID: [17289871](#)
26. Chao A, Wang T-H, Lee Y-S, Hsueh S, Chao A-S, et al. Molecular characterization of adenocarcinoma and squamous carcinoma of the uterine cervix using microarray analysis of gene expression. *Int J Cancer.* 2006; 119: 91–98. PMID: [16450401](#)
27. Wang S, Zhan M, Yin J, Abraham JM, Mori Y, et al. Transcriptional profiling suggests that Barrett's metaplasia is an early intermediate stage in esophageal adenocarcinogenesis. *Oncogene.* 2006; 25: 3346–3356. PMID: [16449976](#)
28. Perou CM, Sørli T, Eisen MB, van de Rijn M, Jeffrey SS, et al. Molecular portraits of human breast tumours. *Nature.* 2000; 406: 747–752. PMID: [10963602](#)
29. Stein T, Price KN, Morris JS, Heath VJ, Ferrier RK, et al. Annexin A8 is up-regulated during mouse mammary gland involution and predicts poor survival in breast cancer. *Clin Cancer Res.* 2005; 11: 6872–6879. PMID: [16203777](#)
30. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. *Proc Natl Acad Sci U S A.* 2003; 100: 8418–8423. PMID: [12829800](#)
31. Goebeler V, Poeter M, Zeuschner D, Gerke V, Rescher U. Annexin A8 Regulates Late Endosome Organization and Function. *Mol Biol Cell.* 2008; 19: 5267–5278. doi: [10.1091/mbc.E08-04-0383](#) PMID: [18923148](#)
32. Poeter M, Brandherm I, Rossaint J, Rosso G, Shahin V, et al. Annexin A8 controls leukocyte recruitment to activated endothelial cells via cell surface delivery of CD63. *Nat Commun.* 2014; 5: 3738. doi: [10.1038/ncomms4738](#) PMID: [24769558](#)

33. Adachi K, Toyota M, Sasaki Y, Yamashita T, Ishida S, et al. Identification of SCN3B as a novel p53-inducible proapoptotic gene. *Oncogene*. 2004; 23: 7791–7798. PMID: [15334053](#)
34. Osada M, Park HL, Nagakawa Y, Begum S, Yamashita K, et al. A novel response element confers p63- and p73-specific activation of the WNT4 promoter. *Biochem Biophys Res Commun*. 2006; 339: 1120–1128. PMID: [16343436](#)
35. Stein T, Morris JS, Davies CR, Weber-Hall SJ, Duffy M-A, et al. Involution of the mouse mammary gland is associated with an immune cascade and an acute-phase response, involving LBP, CD14 and STAT3. *Breast Cancer Res*. 2004; 6: R75–91. PMID: [14979920](#)
36. Gordon KE, Binas B, Chapman RS, Kurian KM, Clarkson RW, et al. A novel cell culture model for studying differentiation and apoptosis in the mouse mammary gland. *Breast Cancer Res*. 2000; 2: 222–235. PMID: [11056687](#)
37. Bornkamm GW, Berens C, Kuklik-Roos C, Bechet JM, Laux G, et al. Stringent doxycycline-dependent control of gene activities using an episomal one-vector system. *Nucleic Acids Res*. 2005; 33: e137. PMID: [16147984](#)
38. Smalley MJ. Isolation, culture and analysis of mouse mammary epithelial cells. In: Ward A, Tosh D, editors. *Methods Mol Biol*. New York: Springer; 2010. pp. 139–170. doi: [10.1007/978-1-60761-756-3_9](#) PMID: [20700710](#)
39. Regan JL, Kendrick H, Magnay FA, Vafaizadeh V, Groner B, et al. c-Kit is required for growth and survival of the cells of origin of Brca1-mutation-associated breast cancer. *Oncogene*. 2012; 31: 869–883. doi: [10.1038/onc.2011.289](#) PMID: [21765473](#)
40. Kendrick H, Regan JL, Magnay FA, Grigoriadis A, Mitsopoulos C, et al. Transcriptome analysis of mammary epithelial subpopulations identifies novel determinants of lineage commitment and cell fate. *BMC Genomics*. 2008; 9: 591. doi: [10.1186/1471-2164-9-591](#) PMID: [19063729](#)
41. McBryan J, Howlin J, Kenny PA, Shioda T, Martin F. ERalpha-CITED1 co-regulated genes expressed during pubertal mammary gland development: implications for breast cancer prognosis. *Oncogene*. 2007; 26: 6406–6419. PMID: [17486082](#)
42. Molyneux G, Geyer FC, Magnay FA, McCarthy A, Kendrick H, et al. BRCA1 basal-like breast cancers originate from luminal epithelial progenitors and not from basal stem cells. *Cell Stem Cell*. 2010; 7: 403–417. doi: [10.1016/j.stem.2010.07.010](#) PMID: [20804975](#)
43. Runkel F, Michels M, Franken S, Franz T. Specific expression of annexin A8 in adult murine stratified epithelia. *J Mol Histol*. 2006; 37: 353–359. PMID: [17082908](#)
44. White AH, Watson REB, Newman B, Freemont AJ, Wallis GA. Annexin VIII is differentially expressed by chondrocytes in the mammalian growth plate during endochondral ossification and in osteoarthritic cartilage. *J Bone Miner Res*. 2002; 17: 1851–1858. PMID: [12369789](#)
45. Stein T, Price KN, Morris JS, Heath VJ, Ferrier RK, et al. Annexin A8 is up-regulated during mouse mammary gland involution and predicts poor survival in breast cancer. *Clin Cancer Res*. 2005; 11: 6872–6879. PMID: [16203777](#)
46. Pece S, Tosoni D, Confalonieri S, Mazzarol G, Vecchi M, et al. Biological and molecular heterogeneity of breast cancers correlates with their cancer stem cell content. *Cell*. 2010; 140: 62–73. doi: [10.1016/j.cell.2009.12.007](#) PMID: [20074520](#)
47. Wansbury O, Mackay A, Kogata N, Mitsopoulos C, Kendrick H, et al. Transcriptome analysis of embryonic mammary cells reveals insights into mammary lineage establishment. *Breast Cancer Res*. 2011; 13: R79. doi: [10.1186/bcr2928](#) PMID: [21834968](#)
48. Nakayama H, Fukuda S, Inoue H, Nishida-Fukuda H, Shirakata Y, et al. Cell surface-annexins regulate ADAM-mediated ectodomain shedding of proamphiregulin. *Mol Biol Cell*. 2012.
49. Cruz AC, Frank BT, Edwards ST, Dazin PF, Peschon JJ, et al. Tumor necrosis factor- α -converting enzyme controls surface expression of c-Kit and survival of embryonic stem cell-derived mast cells. *J Biol Chem*. 2004; 279: 5612–5620. PMID: [14625290](#)
50. Kawaguchi N, Horiuchi K, Becherer JD, Toyama Y, Besmer P, et al. Different ADAMs have distinct influences on Kit ligand processing: phorbol-ester-stimulated ectodomain shedding of Kitl1 by ADAM17 is reduced by ADAM19. *J Cell Sci*. 2007; 120: 943–952. PMID: [17344430](#)
51. Ma Y, Croxton R, Moorer RL, Cress WD. Identification of novel E2F1-regulated genes by microarray. *Arch Biochem Biophys*. 2002; 399: 212–224. PMID: [11888208](#)
52. Piestun D, Kochupurakkal BS, Jacob-Hirsch J, Zeligson S, Koudritsky M, et al. Nanog transforms NIH3T3 cells and targets cell-type restricted genes. *Biochem Biophys Res Commun*. 2006; 343: 279–285. PMID: [16540082](#)
53. Humphreys RC. Programmed cell death in the terminal endbud. *J Mammary Gland Biol Neoplasia*. 1999; 4: 213–220. PMID: [10426400](#)

54. Humphreys RC, Krajewska M, Krnacik S, Jaeger R, Weiher H, et al. Apoptosis in the terminal endbud of the murine mammary gland: a mechanism of ductal morphogenesis. *Development*. 1996; 122: 4013–4022. PMID: [9012521](#)
55. Stein T, Salomonis N, Gusterson BA. Mammary gland involution as a multi-step process. *J Mammary Gland Biol Neoplasia*. 2007; 12: 25–35. PMID: [17431797](#)
56. Clarkson RW, Wayland MT, Lee J, Freeman T, Watson CJ. Gene expression profiling of mammary gland development reveals putative roles for death receptors and immune mediators in post-lactational regression. *Breast Cancer Res*. 2004; 6: R92–109. PMID: [14979921](#)
57. Alldridge LC, Bryant CE. Annexin 1 regulates cell proliferation by disruption of cell morphology and inhibition of cyclin D1 expression through sustained activation of the ERK1/2 MAPK signal. *Exp Cell Res*. 2003; 290: 93–107. PMID: [14516791](#)
58. Chiang Y, Rizzino A, Sibenaller ZA, Wold MS, Vishwanatha JK. Specific down-regulation of annexin II expression in human cells interferes with cell proliferation. *Mol Cell Biochem*. 1999; 199: 139–147. PMID: [10544962](#)
59. Inokuchi J, Narula N, Yee DS, Skarecky DW, Lau A, et al. Annexin A2 positively contributes to the malignant phenotype and secretion of IL-6 in DU145 prostate cancer cells. *Int J Cancer*. 2009; 124: 68–74. doi: [10.1002/ijc.23928](#) PMID: [18924133](#)
60. Monastyrskaya K, Babychuk EB, Hostettler A, Wood P, Grewal T, et al. Plasma membrane-associated annexin A6 reduces Ca²⁺ entry by stabilizing the cortical actin cytoskeleton. *J Biol Chem*. 2009; 284: 17227–17242. doi: [10.1074/jbc.M109.004457](#) PMID: [19386597](#)
61. Theobald J, Smith PD, Jacob SM, Moss SE. Expression of annexin VI in A431 carcinoma cells suppresses proliferation: a possible role for annexin VI in cell growth regulation. *Biochim Biophys Acta*. 1994; 1223: 383–390. PMID: [7918674](#)
62. Goebeler V, Ruhe D, Gerke V, Rescher U. Annexin A8 displays unique phospholipid and F-actin binding properties. *FEBS Lett*. 2006; 580: 2430–2434. PMID: [16638567](#)
63. Hayes MJ, Shao D, Bailly M, Moss SE. Regulation of actin dynamics by annexin 2. *EMBO J*. 2006; 25: 1816–1826. PMID: [16601677](#)
64. Bohn OL, Fuertes-Camilo M, Navarro L, Saldivar J, Sanchez-Sosa S. p16INK4a expression in basal-like breast carcinoma. *Int J Clin Exp Pathol*. 2010; 3: 600–607. PMID: [20661408](#)
65. Sgambato A, Han EK, Zhou P, Schieren I, Weinstein IB. Overexpression of cyclin E in the HC11 mouse mammary epithelial cell line is associated with growth inhibition and increased expression of p27(Kip1). *Cancer Res*. 1996; 56: 1389–1399. PMID: [8640830](#)
66. Sgambato A, Doki Y, Schieren I, Weinstein IB. Effects of cyclin E overexpression on cell growth and response to transforming growth factor beta depend on cell context and p27Kip1 expression. *Cell Growth Differ*. 1997; 8: 393–405. PMID: [9101085](#)
67. Bostrom P, Soderstrom M, Palokangas T, Vahlberg T, Collan Y, et al. Analysis of cyclins A, B1, D1 and E in breast cancer in relation to tumour grade and other prognostic factors. *BMC Res Notes*. 2009; 2: 140. doi: [10.1186/1756-0500-2-140](#) PMID: [19615042](#)
68. Lim E, Vaillant F, Wu D, Forrest NC, Pal B, et al. Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. *Nat Med*. 2009; 15: 907–913. doi: [10.1038/nm.2000](#) PMID: [19648928](#)
69. Payton JE, Grieselhuber NR, Chang LW, Murakami M, Geiss GK, et al. High throughput digital quantification of mRNA abundance in primary human acute myeloid leukemia samples. *J Clin Invest*. 2009; 119: 1714–1726. doi: [10.1172/JCI38248](#) PMID: [19451695](#)
70. Uddin M, Thiruvahindrapuram B, Walker S, Wang Z, Hu P, et al. A high-resolution copy-number variation resource for clinical and population genetics. *Genet Med*. 2014. doi: [10.1038/gim.2014.178](#)